drugset / Trial / NCT01511744

Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine

NCT01511744 ↗

Phase 4 Completed 6000 enrolled Hualan Biological Engineering, Inc.
RandomizedSingle-groupTriple-blindPrevention

Summary

Influenza vaccine (split virion), Inactivated (15ug HA/subtype/0.5ml) of Hualan Biological Bacterin Co., Ltd (The subsidiary of Hualan Biological Engineering INC.) is applicable to the influenza immunity of age 3 and older population. Phase III clinical study was conducted in Jintan City, Jiangsu Province in May, 2006. Trial results showed that this vaccine had good safety and immunogenicity. Hualan Bio Influenza Vaccine obtained its production approval(China Drug Approval No.: S20083016) for marketing on April 3rd, 2008. In order to monitor and evaluate the safety and protective effect against influenza administered on age 3 and older population, therefore we conduct the phase IV clinical trial of the licensed Influenza Vaccine (split virion), Inactivated (15ug HA/subtype/0.5ml).

Timeline

Start
2011-11
Primary completion
2011-11
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Inactivated influenza split vaccine Vaccine 15 ug —

Indications